Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
Globe Newswire•22/10/2026•08:30 ET
0
Key Highlights
- ➤Eupraxia to participate in four healthcare conferences through November 19, 2026
- ➤Virtual Analyst Day will discuss EP-104GI for eosinophilic esophagitis November 13
- ➤EP-104GI remains in Phase 1b/2 RESOLVE trial for EoE
- ➤EP-104GI is an investigational product; safety and efficacy remain unestablished
VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company’s management team will participate in the following upcoming conferences and host a virtual Analyst Day:
Craig Hallum Biotech Catalyst Virtual Conference (October 22(nd), 2026) Format: Fireside Chat & 1x1 Meetings Fireside Chat Date & Time: October 22, 2026, at 10:30am ET Webcast link: Here Location: Virtual
Get started
Create a free account to read the full story.